|By Marketwired .||
|May 27, 2014 08:30 AM EDT||
VALENCIA, SPAIN -- (Marketwired) -- 05/27/14 -- Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," notes a number of recent and relevant articles in the media regarding MRSA and Super-Bugs.
CBS News recently reported on a study showing MRSA is taking up residence in people's homes as well as healthcare settings:
According to the lead researcher at Columbia University Medical Center in New York City, MRSA is now endemic in households. The findings were published on April 21, 2014 in Proceedings of the National Academy of Sciences, based on a study of 161 New York City residents who contracted MRSA infections between 2009 and 2011. People's homes were determined to be major reservoirs of MRSA strain USA300, which is the chief cause of community MRSA infections across the United States.
ScienceDaily has reported on an article in The New England Journal of Medicine about a new highly-resistant MRSA bacterium:
An international research team, at the University of Texas Health Science Center, Houston, has identified this new superbug which caused a bloodstream infection in a Brazilian patient. This case is the first ever reported bloodstream infection caused by a highly vancomycin-resistant MRSA bacteria. Vancomycin is considered the reference standard, least expensive antibiotic used for the treatment of invasive MRSA. What is of particular concern is that genomic analyses indicated that this novel vancomycin-resistant MRSA superbug belongs to a genetic lineage commonly found outside of hospitals and designated as community-associated MRSA.
U.S. News has reported on Electronic Cigarette vapor appearing to increase the virulence of MRSA:
An abstract from a study conducted by the University of California-San Diego and the VA San Diego Healthcare System claims that MRSA cells exposed to the e-cigarette vapour in the lungs of mice with pneumonia were three times more likely to survive than MRSA cells not exposed to the vapour. The lead researcher attributed the greater virulence to a change in pH, prompting the MRSA bacteria to become defensive and less vulnerable to attack.
The Guardian Newspaper in the UK published an article entitled "Return to Victorian-style hospitals to fight superbugs, experts urge":
The article includes a stark warning from scientists who state the danger posed by drug-resistant infections had reached crisis level. To combat this, a return to hospital wards of the type of 100 years ago is proposed, including greater bed separation, lower bed occupancy rates, improved staff-patient ratios and large, open-able windows. Such drastic changes, it is said, are needed to revert to the state of affairs that existed before antibiotics were discovered; "to hold back the spread of resistant bacteria while finding ways to persuade pharmaceutical companies to improve their output of new generations of antibiotics." The article goes on to say that "the problem for medicine is that antibiotics do not offer good returns to shareholders in pharmaceuticals companies."
Zenosense believes that there is an urgent need for an early warning detection device in the battle against MRSA. Such a device would be a useful weapon in the fight against the spread of MRSA and might buy time for the development of new drugs; to combat what appears to be an ever increasing threat.
About Zenosense, Inc.
Zenosense, Inc. is a detection device development company based in Valencia, Spain. Its mission is develop, market and sell an effective MRSA detector, by way of licenced-in technology, for sale to healthcare providers for use in clinical settings. The Company believes there is enormous latent demand for a cost-effective MRSA detector, driven by the costs associated with the late detection of MRSA, and that it has identified a valuable new market segment for a wearable detection device. The development and exclusive license agreement also includes cancer sensory devices. Find out more at www.zenosense.net.
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed on filed on March 26, 2014, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Statements concerning the development of the MRSA detector have been made based on information obtained from Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.